z-logo
open-access-imgOpen Access
Recombinant Human Growth Hormone Plus Recombinant Human Insulin-Like Growth Factor-1 Coadministration Therapy in Short Children with Low Insulin-Like Growth Factor-1 and Growth Hormone Sufficiency: Results from a Randomized, Multicenter, Open-Label, Parallel-Group, Active Treatment-Controlled Trial
Author(s) -
Philippe Backeljauw,
Bradley S. Miller,
Pascale Dutailly,
Aude Houchard,
Elizabeth A. Lawson,
Daniel E. Hale,
Barry Reiner,
Mark A. Sperling
Publication year - 2015
Publication title -
hormone research in paediatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.816
H-Index - 89
eISSN - 1663-2826
pISSN - 1663-2818
DOI - 10.1159/000371799
Subject(s) - medicine , endocrinology , insulin like growth factor , idiopathic short stature , randomized controlled trial , insulin , short stature , growth factor , adverse effect , population , growth hormone treatment , recombinant dna , growth hormone , hormone , biology , receptor , biochemistry , gene , environmental health
Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) both contribute to growth. To determine if recombinant human (rh)GH + rhIGF-1 therapy is more effective than rhGH alone to treat short stature, we assessed the efficacy and safety of coadministered rhGH + rhIGF-1 in short children with GH sufficiency and low IGF-1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom